| 1466 |
National Cancer Institute |
Html |
en |
Penile Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of penile cancer. |
| penile shaft | 0.625965 |
| lower prevalence | 0.447004 |
| disease stage | 0.456978 |
| odds ratio | 0.446539 |
| infected primary lesion | 0.547017 |
| PDQ cancer information | 0.772684 |
| poorly differentiated tumors | 0.538507 |
| clinical trials | 0.807326 |
| observational studies | 0.567664 |
| cancer information summary | 0.707707 |
| breast cancer prevention | 0.552706 |
| bilateral inguinal lymph | 0.695554 |
| penile HPV | 0.678754 |
| NCI’s PDQ | 0.530402 |
| PDQ Adult Treatment | 0.603184 |
| NCI PDQ cancer | 0.668979 |
| stage IV cancer | 0.495897 |
| lymph nodes | 0.744697 |
| regional inguinal lymph | 0.679281 |
| human papillomavirus | 0.609539 |
| positive lymph nodes | 0.642063 |
| penile cancer. | 0.820523 |
| single case | 0.4576 |
| antibiotic therapy | 0.431816 |
| node metastasis | 0.456545 |
|
| United States | 0.583912 |
| new drugs | 0.43228 |
| decreased risk | 0.457358 |
| microscopic node metastases | 0.575056 |
| node dissection | 0.478206 |
| prophylactic lymphadenectomy | 0.435367 |
| penile cancer | 0.96059 |
| National Cancer Institute | 0.555757 |
| distant metastases | 0.467783 |
| PDQ documents | 0.502265 |
| case series studies | 0.559492 |
| precursor lesions progress | 0.546799 |
| local control | 0.438046 |
| Bowen disease | 0.435373 |
| inguinal lymph node | 0.850704 |
| adjunctive inguinal dissection | 0.622563 |
| male newborn circumcision | 0.57819 |
| invasive penile cancer. | 0.789576 |
| case reports | 0.439988 |
| surgical techniques | 0.438147 |
| bilateral ilioinguinal dissection | 0.579916 |
| confidence interval | 0.450369 |
| Inguinal adenopathy | 0.494134 |
| human papillomavirus DNA | 0.562566 |
|
CLICK HERE |
| 1593 |
National Cancer Institute |
Html |
en |
Mistletoe Extracts (PDQ®)–Health Professional Version |
Mistletoe, a semiparasitic plant that grows on several types of trees such as apple, oak, pine and elm, is commonly used in cancer patients in Europe. Read about laboratory and human studies of extracts, such as Iscador and Eurixor, and their effects on quality of life, survival and symptom relief in this expert-reviewed summary. |
| aqueous mistletoe extract | 0.442009 |
| mistletoe lectin-1-standardized extract | 0.441439 |
| mistletoe extracts | 0.647935 |
| recombinant mistletoe lectin | 0.458451 |
| Viscum album var. | 0.395649 |
| viscum album | 0.915234 |
| viscum album extracts | 0.415076 |
| Viscum album L. | 0.758622 |
| mistletoe preparations | 0.534599 |
| orally administered mistletoe | 0.439154 |
| breast cancer patients | 0.419485 |
| galactoside-specific mistletoe lectin | 0.506693 |
| patients | 0.47671 |
| cancer patients | 0.474171 |
| mistletoe | 0.798357 |
| lectin standardized mistletoe | 0.506505 |
| galactoside-specific lectin | 0.442636 |
| galactoside-binding mistletoe lectin | 0.510133 |
| adjuvant mistletoe treatment | 0.475546 |
| mistletoe lectin-induced apoptosis | 0.437043 |
| mistletoe treatment programme | 0.472546 |
| et al. | 0.450682 |
| mistletoe lectin ML-1 | 0.486886 |
| Korean mistletoe lectin | 0.477775 |
|
| mistletoe treatment | 0.507798 |
| PUBMED Abstract | 0.60337 |
| mistletoe extract | 0.555931 |
| Purified mistletoe lectins | 0.438108 |
| Viscum album extract | 0.453589 |
| different mistletoe preparations | 0.423047 |
| Anticancer Res | 0.416126 |
| galactoside-specific mistletoe lectin-1 | 0.433265 |
| mistletoe’s ability | 0.439494 |
| blood mononuclear cells | 0.426242 |
| standardized mistletoe extracts | 0.436989 |
| Gabius HJ | 0.430845 |
| European mistletoe | 0.545426 |
| mistletoe lectin-II-induced apoptosis | 0.4369 |
| breast cancer | 0.430552 |
| aqueous mistletoe preparations | 0.463767 |
| mistletoe lectins | 0.543537 |
| Viscum album preparation | 0.39341 |
| unfermented mistletoe preparations | 0.438537 |
| iscador | 0.417024 |
| mistletoe extract Iscar | 0.429817 |
| mistletoe lectin | 0.642042 |
| cancer | 0.50332 |
| standardized mistletoe extract | 0.492996 |
|
CLICK HERE |
| 1902 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores neuroendocrinos de páncreas (tumores de células de los islotes) (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de células de los islotes (páncreas endocrino). |
| siguientes procedimientos | 0.350148 |
| causa dolores | 0.307246 |
| siguientes aspectos | 0.303943 |
| páncreas causa efectos | 0.320993 |
| pequeña cantidad | 0.31153 |
| células endocrinas | 0.3138 |
| causa debilidad | 0.302846 |
| oclusión arterial hepática | 0.351832 |
| siguientes tipos | 0.303556 |
| vÃa oral | 0.301543 |
| rayos x | 0.302476 |
| pequeños electrodos | 0.301441 |
| ondas sonoras | 0.302366 |
| tumores neuroendocrinos | 0.984556 |
| glucagón causa hiperglucemia | 0.306311 |
| tne pancreático | 0.315238 |
| siguientes riesgos | 0.300896 |
| tratamiento quizás | 0.303501 |
| endocrina múltiple tipo | 0.305298 |
|
| Instituto Nacional | 0.302944 |
| PDQ Tratamiento | 0.311878 |
| ColangiopancreatografÃa retrógrada | 0.302587 |
| Medicamentos bloqueadores | 0.301556 |
| TNE funcionantes | 0.308747 |
| partes distantes | 0.304229 |
| siguientes factores | 0.304155 |
| Physician Data Query | 0.302879 |
| tumores endocrinos | 0.310974 |
| causa sensación | 0.302849 |
| final angosto | 0.303102 |
| siguientes enlaces | 0.301371 |
| Alto contenido | 0.302594 |
| EcografÃa intraoperatoria | 0.302362 |
| Baja concentración | 0.302446 |
| pancreatectomÃa distal | 0.304071 |
| siguientes pruebas | 0.304812 |
| largo tiempo | 0.302722 |
|
CLICK HERE |
| 1907 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia linfoblástica aguda en adultos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda en adultos. |
| siguientes procedimientos | 0.512309 |
| células madre | 0.745172 |
| posibles factores | 0.503357 |
| leucemia linfocÃtica aguda | 0.520357 |
| sudores nocturnos | 0.503905 |
| leucemia linfoblástica aguda | 0.974441 |
| células madre formadoras | 0.514124 |
| hueso compacto | 0.512997 |
| neoplasias mieloides | 0.503724 |
| vÃa oral | 0.502952 |
| rayos x | 0.503057 |
| tirosina cinasa mesilato | 0.506883 |
| enlace drugs approved | 0.528959 |
| largo plazo | 0.502247 |
| cromosoma filadelfia | 0.520834 |
| célula madre mieloide | 0.525688 |
| células t | 0.514618 |
| efectos tardÃos | 0.513015 |
| células anormales.ampliar aspiración | 0.521673 |
| lÃquido cefalorraquÃdeo | 0.529356 |
| punción espinal.Ampliar | 0.503734 |
|
| National Cancer Institute | 0.502969 |
| siguientes riesgos | 0.502423 |
| Instituto Nacional | 0.509996 |
| célula madre linfoide | 0.511194 |
| PDQ Tratamiento | 0.507876 |
| general empeora | 0.503285 |
| presente sección | 0.502319 |
| leucemia mielógena | 0.512372 |
| sistema nervioso central | 0.612 |
| Physician Data Query | 0.510454 |
| linfocitos t | 0.513897 |
| leucemia mieloide aguda | 0.535285 |
| siguientes enlaces | 0.502726 |
| célula madre | 0.560418 |
| células sanguÃneas maduras | 0.551656 |
| células formadoras | 0.516721 |
| Filadelfia".Ampliar Cromosoma Filadelfia | 0.507706 |
| terapia posremisión | 0.505736 |
| cuidado paliativo | 0.502192 |
| siguientes pruebas | 0.518516 |
|
CLICK HERE |
| 1952 |
National Cancer Institute |
Html |
es |
Tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple) (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple). |
| siguientes procedimientos | 0.346148 |
| células madre | 0.945416 |
| causa signos | 0.305542 |
| trasplante autógeno | 0.329369 |
| suficientes glóbulos | 0.313511 |
| siguientes cambios | 0.312466 |
| suficientes células | 0.367406 |
| células madre formadoras | 0.329864 |
| siguientes tipos | 0.318034 |
| siguientes fases | 0.308352 |
| rayos x | 0.307538 |
| causa hipercalcemia | 0.310068 |
| sumario tratamiento | 0.33895 |
| células anormales.ampliar aspiración | 0.361154 |
| causa problemas | 0.309382 |
| Nuevas combinaciones | 0.305801 |
| lesiones óseas | 0.305545 |
| National Cancer Institute | 0.305225 |
| siguientes riesgos | 0.305748 |
| células plasmáticas.GammapatÃa | 0.37332 |
|
| Multiple Myeloma | 0.338693 |
| Instituto Nacional | 0.318628 |
| Plasma Cell Neoplasms | 0.366703 |
| PDQ Tratamiento | 0.31456 |
| presente sección | 0.305256 |
| beta-2 microglobulina | 0.490964 |
| Drugs Approved | 0.337847 |
| siguientes signos | 0.334405 |
| estudio regÃmenes | 0.30494 |
| Physician Data Query | 0.319252 |
| estadio iii | 0.3425 |
| proteÃna m | 0.36173 |
| inhibidor hdac | 0.307303 |
| siguientes enlaces | 0.307028 |
| células sanguÃneas maduras | 0.372655 |
| células b | 0.368037 |
| siguientes pruebas | 0.314313 |
| siguientes sumarios | 0.313298 |
| Other Plasma Cell | 0.367102 |
|
CLICK HERE |
| 2009 |
National Cancer Institute |
Html |
es |
Trasplante de células hematopoyéticas en la niñez (PDQ®)–Versión para profesionales de salud |
Información revisada por expertos acerca del uso del trasplante de células madre hematopoyéticas para el tratamiento del cáncer infantil. |
| mujeres donantes | 0.306393 |
| múltiples incompatibilidades | 0.305809 |
| HLA A | 0.36555 |
| incompatibilidades ich-o | 0.306724 |
| células progenitoras | 0.322599 |
| Sin embargo | 0.310448 |
| mejores abordajes | 0.305856 |
| cordón umbilical mo | 0.310246 |
| bone marrow relapse | 0.305504 |
| células t | 0.3408 |
| Marrow Transplant | 0.341721 |
| Moderado Bajo | 0.314512 |
| donantes momentos | 0.307307 |
| stem cell transplantation | 0.321131 |
| clase ii | 0.317893 |
| donante fraterno | 0.317133 |
| madre hematopoyéticas cmsp | 0.31029 |
| Children's Oncology Group | 0.30909 |
| intensive chemotherapy | 0.305653 |
| TCH satisfactorios | 0.311984 |
| siguientes antÃgenos | 0.307763 |
| donantes mujeres | 0.306338 |
| Transplant Clinical Trials | 0.309697 |
| HLA DRB1 | 0.341366 |
| eich aguda | 0.310608 |
|
| DRB1 HLA DQB1 | 0.319182 |
| dirección r-o | 0.30821 |
| HLA DPB1 | 0.318384 |
| células madre | 0.997289 |
| donantes varones | 0.306485 |
| células cd34+ | 0.310327 |
| leucemia linfoblástica aguda | 0.30978 |
| marrow transplantation versus | 0.305832 |
| bone marrow transplantation | 0.335932 |
| Clinical Trials Network | 0.307815 |
| stem cell | 0.328901 |
| Oncology Group study | 0.308699 |
| células cd34 | 0.331629 |
| antÃgeno hla | 0.332107 |
| Blood Marrow Transplant | 0.306328 |
| células madre hla | 0.331292 |
| eich aguda moderado | 0.306115 |
| PDQ Tratamiento | 0.308981 |
| bone marrow | 0.352242 |
| células progenitoras cd34 | 0.312061 |
| Marrow Transplant Research | 0.305769 |
| células madre resultante | 0.314653 |
| incompatibilidades r-o | 0.306646 |
| EICH crónica | 0.314484 |
|
CLICK HERE |
| 2077 |
National Cancer Institute |
Html |
es |
Pruebas genéticas para síndromes hereditarios de cáncer |
Trata de pruebas genéticas para riesgos heredados de cáncer; incluye tipos de pruebas, para quién son, explicación y confidencialidad de los resultados. Ofrece información de pruebas genéticas a domicilio o pruebas para el consumidor. |
| paciente grupos | 0.426785 |
| ningún efecto | 0.430963 |
| direct-to-consumer genetic testing | 0.524243 |
| Clinical Chemistry | 0.427805 |
| Privacy Rule | 0.424134 |
| Accountability Act | 0.423749 |
| gen mutante | 0.448711 |
| Clinical Laboratory Improvement | 0.443406 |
| copia mutante | 0.438081 |
| seguro médico | 0.523691 |
| valiosa oportunidad | 0.42438 |
| gen alteraciones | 0.444199 |
| Topol E | 0.422575 |
| profesionales genéticos | 0.423689 |
| información genética | 0.694265 |
| PubMed Abstract | 0.469151 |
| PMC Article | 0.422751 |
| pruebas genéticas caseras | 0.933419 |
| Clinical Oncology | 0.46864 |
| reliable or risky | 0.440953 |
| GWAS)Â por medio | 0.422097 |
| pequeña porción | 0.422164 |
| hijo hereda | 0.4346 |
| leyes gina | 0.4236 |
| determinada persona | 0.471237 |
|
| profesional conocedor | 0.425068 |
| negativo carente | 0.503682 |
| Health Information Portability | 0.441872 |
| cuidado preventivo | 0.422328 |
| Clinical Oncology Policy | 0.44516 |
| ASHG statement | 0.425726 |
| genomic testing | 0.424164 |
| conocida mutación | 0.495717 |
| falsa seguridad | 0.422355 |
| Genética Humana | 0.494712 |
| Javitt G | 0.4224 |
| Federal Trade Commission | 0.438077 |
| Human Genetics | 0.422666 |
| cabo pruebas | 0.510628 |
| antecedentes familiares | 0.466262 |
| pruebas quizás | 0.52233 |
| posibles alternativas | 0.424779 |
| complicada decisión | 0.427954 |
| estudios por asociación | 0.422415 |
| profesional genético | 0.434126 |
| negativo falso | 0.497922 |
| hijos hombres | 0.425049 |
| llama portadores | 0.430487 |
| llamadas polimorfismos | 0.425347 |
|
CLICK HERE |
| 4388 |
National Cancer Institute |
Html |
en |
Risk Factors for Cancer |
Information about behaviors, exposures, and other factors that may influence the risk of cancer. |
| possible inherited cancer | 0.579042 |
| sign | 0.325482 |
| section | 0.325244 |
| protective factors | 0.646351 |
| avoidable risk factors | 0.633812 |
| media | 0.323442 |
| type | 0.323483 |
| certain behaviors | 0.496195 |
| wrong ideas | 0.432065 |
| research | 0.328222 |
| result | 0.323043 |
| true risk factor | 0.577461 |
| things | 0.325771 |
| Common Cancer Myths | 0.549129 |
| Hereditary Cancer Syndromes | 0.581459 |
| Misconceptions page | 0.432753 |
| relationship | 0.322662 |
| increased risk | 0.439428 |
| chemicals | 0.326011 |
| potential risk factor | 0.567711 |
| risk factors | 0.923045 |
| certain substances | 0.487633 |
|
| genetic mutations | 0.443709 |
| chance | 0.323016 |
| protective risk factors | 0.672248 |
| certain cancers | 0.611938 |
| lower risk | 0.460281 |
| epidemiology studies | 0.437177 |
| large groups | 0.438561 |
| finding | 0.323802 |
| people | 0.373455 |
| certain risk factors | 0.746622 |
| exposure | 0.356743 |
| chances | 0.333077 |
| scientists | 0.343939 |
| family history | 0.579318 |
| certain ways | 0.482584 |
| person | 0.360237 |
| Cancer risk factors | 0.679541 |
| n’t | 0.355491 |
| cancer | 0.820183 |
| information | 0.349749 |
| similar association | 0.428532 |
| possible mechanism | 0.423041 |
|
CLICK HERE |
| 16643 |
National Cancer Institute |
Html |
es |
Régimen Gonzalez (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del régimen Gonzalez como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.304069 |
| New Hampshire Avenue | 0.301293 |
| Drug Administration | 0.300803 |
| estadio ii | 0.30117 |
| NCI Best Case | 0.302468 |
| datos bibliográficos pubmed | 0.301383 |
| siguientes preguntas | 0.300833 |
| supervivencia promedio | 0.301242 |
| James Beard | 0.301166 |
| PDQ Régimen Gonzalez | 0.309993 |
| National Cancer Institute | 0.301582 |
| estudio clÃnico | 0.301423 |
| siguientes riesgos | 0.301039 |
| Instituto Nacional | 0.310951 |
| Salud Complementaria | 0.305346 |
| Visuals Online | 0.30094 |
| complementarias revisa | 0.301324 |
| siguientes efectos | 0.301323 |
|
| Physician Data Query | 0.305467 |
| enzimas pancreáticas | 0.367516 |
| Estados Unidos | 0.312379 |
| régimen gonzalez | 0.988904 |
| libre uso | 0.300947 |
| página manejo | 0.300877 |
| Medicina Alternativa | 0.30166 |
| ¿El tratamiento | 0.301547 |
| ¿Los beneficios | 0.30081 |
| juntos cam | 0.300775 |
| siguientes formas | 0.301287 |
| William Kelley | 0.301175 |
| Clinical Oncology | 0.301179 |
| Nicholas Gonzalez | 0.323344 |
| Max Gerson | 0.301216 |
| enzimas.Los resultados | 0.300995 |
| Series Program | 0.300797 |
| medicina complementaria | 0.336883 |
|
CLICK HERE |
| 17276 |
National Cancer Institute |
Html |
es |
Su propio cuidado |
Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. Es importante que también se cuide a usted mismo y que pida ayuda. |
| Lotsa Helping Hands | 0.77931 |
| busque ayuda | 0.925738 |
|
|
CLICK HERE |